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Previewsthe upstream regulators of the p53 tumor
suppressor, the guardian of the genome
against DNA mutations. Second, the
titration of potential therapeutic drugs
would be difficult, as the response to the
ROS burst is biphasic: some ROS is
necessary for the cellular responses to
hypoxia, including (tumor) angiogenesis,
while too much is deleterious for the
angiogenic endothelium, as seen in the
case of ATM deficiency.
The regulation of endothelial oxygen
sensing and metabolism is certainly
an area where additional angiogenesis
inhibitors could be explored, and the
paper by Okuno et al. reveals one striking
example of success with this approach.
Current angiogenesis inhibitors provoke
at least transient hypoxia before vessel288 Cell Metabolism 16, September 5, 2012 ªnormalization, and inhibition of the
pathway identified by Okuno et al. could
be particularly effective in this context.
The immature, growing endothelium that
is subject to angiogenic factor stimulation
seems to be particularly sensitive to
ROS generation during hypoxia, and the
selective effect of the ATM pathway
would thus increase the targeting speci-
ficity. Undoubtedly, the importance of
the ROS-ATM-p38 pathway should also
be further explored in other vascular
disease processes such as atheroscle-
rosis and hypertension.REFERENCES
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The cellular origins and molecular determinants of brown adipose tissue (BAT) are the focus of renewed
attention. Serendipitous studies examining hematopoiesis in human pluripotent stem cell cultures (Nishio
et al., 2012, in this issue of Cell Metabolism) now identify cytokines capable of inducing BAT differentiation
from these human stem cells and suggest a link between BAT and blood cells.Brown adipose tissue (BAT) has the
unique ability to act as a nonshivering
thermogenic organ. When rodents are
exposed to cold environments or treated
with b3-adrenergic agonists, their BAT
increases in volume and undergoesmeta-
bolic changes. This is accompanied by
increased numbers of mitochondria,
giving the tissue its brown color, and the
induced expression of uncoupling protein
1 (UCP1). UCP1 is found in mitochondria,
where it is responsible for short circuiting
the mitochondrial proton gradient, there-
by converting energy directly into heat.
For small animals with large surface area
to volume ratios and for newborn humans,
BAT protects critical organs (heart,
kidney, aorta) against cold environments
by maintaining their core body tempera-
ture. Until recently, many investigatorsthought that BAT disappeared during
human development; however, sophisti-
cated radiological imaging technologies
have uncovered the persistence of BAT
in adult human subjects, where it has
been associated with a lean, rather than
obese, phenotype. Consequently, uncov-
ering a mechanism to prevent adipose
tissue progenitor cells from selecting
a white for a brown adipocyte differentia-
tion pathway has been a ‘‘holy grail’’ for
some obesity researchers. The pioneering
discovery of the brown adipocyte-selec-
tive zinc finger transcription factor,
PRDM16, was a critical milestone in this
field (Seale et al., 2007). Seale and
colleagues demonstrated that transduc-
tion of PRDM16 into white adipocyte
progenitors led to their conversion into
thermogenic brown adipocytes (Sealeet al., 2007). A subset of white adipose
cells, known both as ‘‘beige’’ or ‘‘brite’’
cells, undergo thermogenic differentiation
upon exposure to prostaglandins (Ishiba-
shi and Seale, 2010; Vegiopoulos et al.,
2010). Likewise, treatment of murine
adipocyte progenitor cells with bone
morphogenetic protein 7 (BMP7) has
been found to induce PRDM16 expres-
sion and conversion into brown adipo-
cytes (Tseng et al., 2008); however, this
protocol has displayed variable efficiency
when performed with human white adipo-
cyte progenitors (Schulz et al., 2011).
Thus, the mechanism underlying human
brown adipogenesis may not be identical
to that of the murine system. Since
pharmacological induction of human
BAT has promise to prevent or treat
obesity, there is a need for reliable and
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Previewsreproducible source of human brown adi-
poctyes as a discovery tool for identifying
and validating potential therapeutic mole-
cules. In this issue of Cell Metabolism,
Nishio and colleagues describe that
what started as a hematopoietic cytokine
cocktail to induce human embryonic and
induced pluripotent stem cells (hPSCs)
can promote brown adipogenesis (Nishio
et al., 2012).
The authors made their findings seren-
dipitously while searching for a combina-
tion of cytokines that would convert
hPSCs into hematopoietic lineages. Prior
in vitro studies of hematopoiesis had
identified adherent stromal cells as a
‘‘feeder layer’’ required as a source of
cytokines to promote the proliferation
and differentiation of hematopoietic stem
cells (HSCs). To avoid using such a
stromal feeder layer, the authors supple-
mented hPSCs with a cocktail containing
cytokines previously known to drive
hematopoiesis (BMP7, FLT3 ligand, inter-
leukin-6 [IL-6], stem cell factor, and
vascular endothelial factor). Unexpect-
edly, the authors noted not only the
formation of hematopoietic lineage cells
but also the appearance of an adherent
feeder layer containing adipogenic
stromal cells (Nishio et al., 2012). Unlike
white adipocytes, which contain large
lipid vacuoles that can coalesce into
a single vacuole (unilocular), the hPSC-
derived adherent stromal cells contained
multiple small lipid vacuoles (multilocular)
and abundant mitochondria, which are
characteristic of brown adipocytes.
Removal of any one of the cytokines
reduced brown adipogenesis by the
hPSCs, as did small molecule inhibitors
of the BMP receptor, AKT, and p38 MAP
kinase pathways. The authors showed
in vitro that the hPSC-derived brown
adipocytes (hPSC dBAs) displayed high
oxygen consumption rates in response
to b3-adrenergic agonists. When the
hPSC dBAs were transplanted subcuta-
neously into mice, the recipients dis-
played lower serum triglyceride levels,
reduced fasting blood glucose levels,
and improved oral glucose tolerancetesting when compared to controls,
consistent with enhanced BAT function.
Furthermore, UCP1 and PRDM16 were
present in RNA extracted from human
bone marrow fat, and PET/CT imaging
detected the characteristic cold-stimu-
lated glucose uptake associated with
BAT in the marrow of human subjects.
The identification of cytokines capable
of inducing human brown adipocyte
differentiation in the hPSCs raises further
mechanistic questions. Which metabolic
pathways other than AKT, MAPK, and
BMP receptor are required? Are tran-
scription factor families such as the
STATs, mediating the IL-6 pathway, or
Smads, mediating BMP, critical players?
At the basic science level, this study
represents a substantial step forward by
defining a human cell model for brown
adipocyte differentiation suitable for
in vitro hypothesis testing. Moreover, it
now validates hPSCs as a reproducible
model for high-throughput screening of
human brown adipogenic agonists and
antagonists suitable for pharmaceutical
discovery.
The connections between brown fat
and the bone marrow may not be entirely
unexpected. The earliest hints linking
bone marrow stroma to BAT were
described by the Nobel Prize winner
Charles Huggins, who also was among
the first to discover the osteogenic
actions of BMPs. Huggins found that
rodents exposed to low ambient tempera-
tures increased their marrow adiposity,
similar to the induction of BATs with cold
exposure (Huggins and Blocksom, 1936;
Huggins et al., 1970). More recently, the
Lecka-Czernik laboratory found that
murine bone marrow-derived adipocytes
displayed temperature-inducible expres-
sion of Ucp1 and Prdm16, consistent
with the current human marrow findings
(Krings et al., 2011).
Finally, this work has potential implica-
tions for tissue-engineering approaches
to the treatment of metabolic disorders.
Plastic surgeons routinely perform adi-
pose tissue grafts, so implants of engi-
neered BAT are a theoretical treatmentCell Metabolism 16, Sfor obesity (Tran and Kahn, 2010).
However, regulatory authorities have
substantial concerns regarding the safety
of viral and nonviral gene transduction
methods in human subjects. Conse-
quently, PRDM16 transduction is unlikely
to receive approval in the immediate
future. Instead, the use of a hemopoietin
cocktail to induce autologous hPSC
ex vivo to create a tissue-engineered
BAT for subsequent subcutaneous
implantation in obese patients may fare
better in gaining approval for clinical
safety and efficacy trials.
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